Department of Oral Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai China.
Shanghai Key Laboratory of Stomatology, Shanghai, China.
Histol Histopathol. 2018 Apr;33(4):379-388. doi: 10.14670/HH-11-933. Epub 2017 Sep 19.
Protein tyrosine kinase 7 (PTK7) is a member of receptor protein tyrosine kinase-like molecules, which is involved in tumorigenesis. However, the association between PTK7 expression and its pathological significance in survival prognosis remains under investigation. The purpose of this meta-analysis is to clarify the prognostic value of PTK7 expression in human malignancies.
A comprehensive literature search was performed in databases of PubMed, Embase and Cochrane Library. The statistical procedures were conducted by Stata 14.0 and the effect size was displayed by model of relative risk. Subgroup analyses were additionally implemented to disclose the potential confounding elements. Sensitivity analysis was used for evaluating the outcome stability, both Begg's test and Egger's test were utilized to detect the publication bias across the included studies.
We identified 11 studies published with a total sample-size of 2431 participants. Patients with higher PTK7 expression were significantly associated with cancer risk (RR =2.995, 95% CI: 1.048-8.56, p=0.041, random model), and histological grade (RR = 0.696, 95% CI: 0.499-0.972, p=0.033, random model). PTK7 was also found to be an unfavorable prognostic marker for overall survival (HR = 2.621 95% CI: 1.980-3.468, p=0.000, fixed model) and shorter disease free survival (HR =2.242, 95% CI: 1.112-4.521, p=0.024, random model).
Higher expression of PTK7 significantly indicates worse prognosis in human malignancies.
蛋白酪氨酸激酶 7（PTK7）是受体酪氨酸激酶样分子家族的一员，参与肿瘤的发生。然而，PTK7 表达与生存预后的病理意义之间的关联仍在研究中。本荟萃分析的目的是阐明 PTK7 表达在人类恶性肿瘤中的预后价值。
在 PubMed、Embase 和 Cochrane Library 数据库中进行全面的文献检索。统计过程由 Stata 14.0 执行，效应大小通过相对风险模型显示。此外，还进行了亚组分析以揭示潜在的混杂因素。敏感性分析用于评估结果的稳定性，通过 Begg 检验和 Egger 检验检测纳入研究的发表偏倚。
我们确定了 11 项发表的研究，共有 2431 名参与者。PTK7 表达较高的患者与癌症风险显著相关（RR=2.995，95%CI：1.048-8.56，p=0.041，随机模型），与组织学分级也显著相关（RR=0.696，95%CI：0.499-0.972，p=0.033，随机模型）。PTK7 也是总生存期（HR=2.621，95%CI：1.980-3.468，p=0.000，固定模型）和无病生存期（HR=2.242，95%CI：1.112-4.521，p=0.024，随机模型）较短的不良预后标志物。
PTK7 表达较高显著表明人类恶性肿瘤的预后较差。
